(R)-SKBG-1
Based on 2 publication(s) in Google Scholar
(R)-SKBG-1 is a covalent inhibitor targeting the RNA binding protein NONO. (R)-SKBG-1 can reduce the expression of androgen receptor (AR) and its splice variants, inhibiting cancer cell proliferation. (R)-SKBG-1 inhibits androgen receptor expression with IC50 of 3.1 μM and 5.5 μM for AR-FL mRNA and AR-V7 mRNA, respectively. (R)-SKBG-1 interferes with the gene regulatory network of cancer cells and inhibits cancer cell growth by stabilizing the interaction between NONO and mRNA. (R)-SKBG-1 can be used in the study of cancers related to NONO dysfunction, such as prostate cancer.
For research use only. We do not sell to patients.
- Purity: 99.68%
- CAS No.: 2955634-67-8
- Formula: C22H26ClN3O6S
- Molecular Weight:495.98
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Cancer Compound Library
HY-L025
-
Transcription Factor-Targeted Library
HY-L090
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Nuclear Receptor Compound Library
HY-L126
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) (R)-SKBG-1
More
Biological Activity
IC50: 3.1 μM (AR-FL mRNA), 5.5 μM (AR-V7 mRNA)[1]
(R)-SKBG-1 (20 μM; 4 h and 24 h) significantly downregulated approximately 1,000 mRNAs in 22Rv1 cells in RNA sequencing experiments of 22Rv1 and sgNONO 22Rv1 cells, indicating that most of these transcriptome changes depend on the presence of NONO[1].
(R)-SKBG-1 (20 μM; 4 h) enhanced the interaction between NONO and mRNA in eCLIP-seq experiments of 22Rv1 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2955634-67-8
-
Appearance Solid
-
Molecular Weight 495.98
-
Formula C22H26ClN3O6S
-
Color White to yellow
-
SMILES
O=S(N1[C@@H](C(NCC2=CC=C(OC)C=C2)=O)CN(C(CCl)=O)CC1)(C3=CC=C(OC)C=C3)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Int J Mol Sci
2025 Sep 2;26(17):8542. PMID: 40943463 -
Solvent & Solubility
DMSO : 100 mg/mL (201.62 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (5.04 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Kathman SG, et al. Remodeling oncogenic transcriptomes by small molecules targeting NONO. Nat Chem Biol. 2023 Jul;19(7):825-836. [Content Brief]
[2]. Takeiwa T, et al. Role of RNA binding proteins of the Drosophila behavior and human splicing (DBHS) family in health and cancer. RNA Biol. 2024 Jan;21(1):1-17. [Content Brief]
[3]. Schmeing S, et al. Challenges in Therapeutically Targeting the RNA-Recognition Motif. Wiley Interdiscip Rev RNA. 2024 Nov-Dec;15(6):e1877. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0162 mL | 10.0811 mL | 20.1621 mL | 50.4053 mL |
| 5 mM | 0.4032 mL | 2.0162 mL | 4.0324 mL | 10.0811 mL | |
| 10 mM | 0.2016 mL | 1.0081 mL | 2.0162 mL | 5.0405 mL | |
| 15 mM | 0.1344 mL | 0.6721 mL | 1.3441 mL | 3.3604 mL | |
| 20 mM | 0.1008 mL | 0.5041 mL | 1.0081 mL | 2.5203 mL | |
| 25 mM | 0.0806 mL | 0.4032 mL | 0.8065 mL | 2.0162 mL | |
| 30 mM | 0.0672 mL | 0.3360 mL | 0.6721 mL | 1.6802 mL | |
| 40 mM | 0.0504 mL | 0.2520 mL | 0.5041 mL | 1.2601 mL | |
| 50 mM | 0.0403 mL | 0.2016 mL | 0.4032 mL | 1.0081 mL | |
| 60 mM | 0.0336 mL | 0.1680 mL | 0.3360 mL | 0.8401 mL | |
| 80 mM | 0.0252 mL | 0.1260 mL | 0.2520 mL | 0.6301 mL | |
| 100 mM | 0.0202 mL | 0.1008 mL | 0.2016 mL | 0.5041 mL |
Powered by Bioz